Overview

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis

Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The study shall explore whether treatment of atopic dermatitis is equally effective with Phoenix medical device as compared to standard therapy (Hydrocortisone cream).
Phase:
N/A
Details
Lead Sponsor:
Bayer
Treatments:
Cortisol succinate
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate